Ivan Kairatov is a seasoned voice in biopharmaceutical innovation, specializing in the complex intersections of metabolic signaling and oncology. With years spent navigating the intricacies of research and development, he has witnessed how the industry struggles to tackle the secondary symptoms of chronic illness that often prove more fatal than the primary disease itself. Today, he joins us to discuss a breakthrough in our understanding of cachexia—a devastating wasting syndrome that has long remained one of the most stubborn metabolic hurdles in cancer treatment.
In this conversation, we explore the physiological mechanics behind why lung cancer patients experience rapid weight loss and how specific tumor subtypes act as biological puppet masters. We delve into the “lung-brain superhighway” that allows cancer cells to communicate with the central nervous system through local sensory neurons. Kairatov also explains the surprising role of dietary fats and the molecule prostaglandin E2 (PGE2), highlighting how common medications and simple nutritional shifts could potentially stop this metabolic hijacking before it destroys a patient’s quality of life.
Cachexia accounts for a quarter of cancer fatalities through severe muscle and fat depletion. From your perspective in biopharma R&D, why has this syndrome been so difficult to target, and how does this new research change the paradigm?
Historically, the biopharma world viewed cachexia as an inevitable side effect of late-stage disease rather than a primary enemy that could be surgically targeted. It is a gut-wrenching sight to see patients literally wasting away, with their bodies consuming their own muscle and fat just to keep the lights on during the fight against a chronic illness. When you consider that this syndrome contributes to 25% of all cancer deaths and affects roughly 9 million people globally, including those with cardiovascular disease or Alzheimer’s, the scale of the medical need is immense. For a long time, we assumed this was just the result of general inflammation or “circulating immune factors” floating through the blood. This new research published in July 2026 shifts our focus from the general immune system to a specific, direct strike on the nervous system, revealing that the body isn’t just running out of fuel—it’s being actively told to starve itself by the tumor.
One of the major hurdles in biomedical research is the gap between laboratory models and human reality. How did the development of more physiologically accurate models lead to the discovery that only certain lung cancer subtypes trigger this wasting?
For years, we were essentially flying blind because our laboratory models didn’t mirror the human experience; we had tumors growing in the wrong places or at sizes that didn’t make physiological sense relative to the host. In many earlier experiments, the lack of accurate scaling meant we couldn’t see the subtle communication happening between an organ and the brain. By creating models where tumors are situated in the lungs at realistic scales, researchers finally observed that not all lung cancers are created equal in their ability to destroy tissue. They identified a specific genetic subset that was far more aggressive in promoting cachexia than others, a finding that would have been lost in a less precise model. This realization that the tumor’s location and its specific genetic makeup dictate the metabolic outcome is a massive leap forward for translational medicine, allowing us to be much more specific in how we screen patients for risk.
The idea of a tumor “hijacking” the nervous system sounds like something out of a thriller. Could you explain the mechanism by which these tumors communicate with the brain to effectively control patient behavior?
It really is a high-stakes game of biological sabotage where the tumor taps into the lung’s local sensory neurons to send distress signals directly to the brain. This “lung-brain superhighway” was previously known to help the body recognize infections like the flu and promote that “sick feeling,” but we now know these tumors have learned to use that same pathway to manipulate the host. By hijacking these peripheral nerves, the tumor tricks the brain into suppressing appetite and ramping up the demand for energy, which is why we see such rapid depletion of fat and muscle. When the research team experimentally silenced these nerves or cut the communication line, they effectively stopped the tumor from being able to “talk” to the brain. This prevented the brain from triggering the cachexia response, which suggests that the nervous system is a critical, and perhaps even the primary, driver of this wasting.
There is a counterintuitive finding in this study regarding nutrition, where high-calorie, high-fat diets actually accelerated the decline. What is the molecular basis for this reaction, and how does PGE2 bridge the gap between diet and the nervous system?
This is perhaps the most striking part of the findings: when researchers tried to help the mice by feeding them high-calorie, high-fat diets to gain weight, the cachexia actually got worse. The culprit is a lipid signaling molecule called prostaglandin E2, or PGE2, which is well known for inducing symptoms like fever and is synthesized from animal fats, specifically omega-6 fatty acids. These tumors produce much higher levels of PGE2 than other subtypes, and they use it as their primary language to signal the sensory neurons in the lungs. By fueling the body with more of these specific fats, we were inadvertently giving the tumor more raw material to create these “starvation signals.” It is a visceral reminder that the metabolic environment we provide for a patient can completely change the signaling frequency of the disease.
The study suggests that common over-the-counter medications and dietary changes might mitigate these effects. How significant is the potential for repurposing existing drugs versus developing new molecular targets in this context?
Seeing a clear link between a dietary switch and the suppression of PGE2 production opens up a whole new toolbox for clinicians that doesn’t necessarily require a ten-year drug development cycle. In the study, the team found that by simply switching to a diet focused on omega-3 fatty acids, the tumors could no longer effectively communicate with the nervous system to cause wasting. Furthermore, the use of everyday medications like aspirin and ibuprofen, which block the body’s ability to make PGE2, showed success in smaller trials at preventing the development of cachexia symptoms. This is incredibly promising because it suggests we can improve patient outcomes right now by combining nutritional therapy with existing pharmacology. While we will still search for more potent, specific molecules to block these pathways, the ability to intervene today with tools already in our medicine cabinets is a major win for patient care.
What is your forecast for the future of personalized oncology care now that we understand this neurological connection?
My forecast for the next decade of oncology involves a move toward “neurometabolic” care, where we treat the tumor and the patient’s nervous system as a single, integrated unit. Once we pin down the exact circuits in the brain that these lung tumors connect to, I suspect we will find they are also responsible for other debilitating symptoms like depression or the memory loss often seen in cancer patients. I expect we will see the emergence of highly tailored treatments that don’t just kill cancer cells, but also shield the brain and metabolism from the tumor’s toxic influence through specific dietary protocols and nerve-blocking therapies. We are moving toward a world where a cancer diagnosis doesn’t have to mean the inevitable loss of one’s physical and mental self, because we finally understand how the tumor is trying to take control.
